iBio, Inc. (IBIO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025, and the nine months ended March 31, 2025. iBio, Inc. is a preclinical-stage biotechnology company leveraging Artificial Intelligence (AI) and Machine Learning (ML) to develop precision antibodies for hard-to-drug targets. The company has transitioned from a Contract Development and Manufacturing Organization (CDMO) to an AI-enabled biotech firm, completing the divestiture of its CDMO facility in May 2024. As of March 31, 2025, the company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2025 | As of Mar 31, 2025 |
|---|---|---|---|
| Revenue | $0 | $200,000 | N/A |
| Net Loss (Continuing Ops) | $(4.86) million | $(13.21) million | N/A |
| Operating Expenses | $(4.88) million | $(13.60) million | N/A |
| Cash & Cash Equivalents | N/A | N/A | $4.96 million |
| Total Current Assets | N/A | N/A | $6.06 million |
| Total Current Liabilities | N/A | N/A | $5.40 million |
| Accumulated Deficit | N/A | N/A | $(327.06) million |
| Weighted Avg Shares Outstanding | 9.86 million | 9.20 million | N/A |
Note: All figures in millions unless otherwise noted. Revenue for the nine-month period consisted of $200,000 from services provided to a collaborative partner.
Material Changes vs. Prior Period
- Revenue: No revenue was recognized in the three months ended March 31, 2025, compared to zero in the prior year quarter. For the nine months, revenue increased to $200,000 from $50,000 in the prior year period.
- Operating Expenses: Total operating expenses increased to $4.88 million for the quarter (from $3.63 million) and $13.60 million for the nine months (from $13.28 million). The increase in R&D expenses ($1.91M vs $0.90M for the quarter) was driven by higher spending on consultants, outside services, and personnel.
- Discontinued Operations: The company reported no loss from discontinued operations in the current period, compared to a loss of $0.54 million in the prior year quarter and $4.93 million in the prior year nine-month period. The CDMO facility was sold in May 2024.
- Liquidity: Cash and cash equivalents decreased from $14.21 million as of June 30, 2024, to $4.96 million as of March 31, 2025, reflecting a net cash burn of approximately $10.7 million from operating activities over the nine-month period.
Guidance, Outlook, and Risks
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date due to recurring losses, negative cash flows, and limited cash resources. The company anticipates needing additional financing to fund operations.
Recent Financing & Capital Events (Subsequent to Period End):
- Warrant Inducement: On April 29, 2025, the company entered an agreement to induce holders to exercise existing warrants. This resulted in the exercise of warrants for 5.63 million shares and the issuance of new inducement warrants for 11.25 million shares, generating approximately $6.2 million in gross proceeds.
- ATM Sales: The company sold 22,812 shares under its At-The-Market (ATM) agreement in April 2025 for net proceeds of approximately $60,000.
- License Agreements: In April 2025, the company entered an exclusive license agreement with AstralBio for an Activin E antibody, utilizing a $750,000 credit from a prior collaboration.
Pipeline Updates: The company is advancing preclinical programs in obesity/cardiovascular disease (IBIO-600 targeting myostatin) and immuno-oncology (IBIO-101, TROP-2 x CD3, MUC16 x CD3). Management plans to pause further development of IBIO-101 unless additional funding is secured, focusing instead on partnering opportunities.
Risks: Key risks include the inability to raise additional capital, potential impairment of indefinite-lived intangible assets (specifically the IBIO-101 IP), and the uncertainty of clinical success for preclinical candidates.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$10.5 million cash position (as of May 1, 2025, post-warrant exercise) to fund operations through Q1 FY2026 and the timeline for the next capital raise.
- Going Concern Status: Review the specific mitigation strategies management is pursuing to resolve the substantial doubt regarding the company's ability to continue as a going concern.
- Dilution Impact: Assess the dilutionary effect of the recent warrant inducement (11.25 million new warrants issued) and the existing warrant overhang on future earnings per share.
- Asset Impairment: Monitor the valuation of the $5.0 million indefinite-lived intangible asset (IBIO-101) for potential impairment triggers given the decision to pause development.
- Collaboration Milestones: Track the progress of the AstralBio collaboration and the potential for future milestone payments or out-licensing revenue.